BioNTech SE (22UA) — Free Cash Flow Generation Index
Latest as of December 2025:
0.80x
BioNTech SE (22UA) has a Free Cash Flow Generation Index of 0.80x as of December 2025. Free cash flow of €247.40 Million represents 1% of operating cash flow (€309.50 Million). Read how much debt does BioNTech SE carry for a breakdown of total debt and financial obligations.
FCF Generation Index
0.80x
Free Cash Flow / Operating CF
Free Cash Flow
€247.40 Million
EUR
Operating Cash Flow
€309.50 Million
EUR
Capital Expenditures
€62.10 Million
EUR
BioNTech SE Free Cash Flow Generation Index (2021–2025)
Historical FCF Generation Index trend for BioNTech SE across 5 annual periods. Explore BioNTech SE (22UA) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Annual Free Cash Flow Generation for BioNTech SE (2021–2025)
Year-by-year Free Cash Flow Generation Index for BioNTech SE. For the full company profile including market capitalisation, see 22UA market cap overview.
| Year | FCG Index | Free Cash Flow (EUR) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.64x | €-293.00 Million | €456.00 Million | €749.00 Million | ▲ +45.4% |
| 2024 | -1.18x | €-244.60 Million | €207.70 Million | €452.30 Million | ▼ -235.6% |
| 2023 | 0.87x | €4.67 Billion | €5.37 Billion | €705.50 Million | ▼ -10.7% |
| 2022 | 0.97x | €13.21 Billion | €13.58 Billion | €363.30 Million | ▲ +17.7% |
| 2021 | 0.83x | €735.70 Million | €889.70 Million | €127.50 Million | — |
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).